Brianne Pfannenstiel, Reporter-Kansas City Business Journal
Stason Pharmaceuticals Inc. announced Friday that it’s moving its brand division from Irvine, Calif. to Kansas City, Kan.
The holding company will be called KC Specialty Therapeutics LLC. That division of the company focuses on developing drugs for human “orphan” diseases, which are those that affect a relatively small number of patients every year.
Stason recently announced it would relocate the corporate headquarters of its animal health division, Stason Animal Health Inc., to the Bioscience & Technology Business Center located on The University of Kansas Medical Center campus. KC Specialty Therapeutics will also be located in the BTBC.
Diana Wood, vice president of corporate development for Stason Pharmaceuticals and CEO for KC Specialty Therapeutics, said in an interview that the company expected to hire about 10 to 15 people locally during the next year.
“Stason Pharmaceuticals has been very impressed with the biosciences opportunities in the Kansas City region since moving Stason Animal Health’s national headquarters here earlier this year,” Wood said in a statement.
“The KC Animal Health Corridor and broader life sciences community have been incredibly supportive, proving that KC is the best place for Stason Pharmaceuticals, and our new holding company KC Specialty Therapeutics, to grow in national prominence.”
The Stason group employs about 120 people worldwide.